Impact of hepatitis C treatment on long-term outcomes for patients with hepatocellular carcinoma: a United States Safety Net Collaborative Study

Michael K. Turgeon, Rachel M. Lee, Adriana C. Gamboa, Adam Yopp, Emily L. Ryon, Neha Goel, Annie Wang, Ann Y. Lee, Sommer Luu, Cary Hsu, Eric Silberfein, Shishir K. Maithel, Maria C. Russell

Research output: Contribution to journalArticle

Abstract

Background: Widespread HCV treatment for hepatocellular carcinoma (HCC) patients remains limited. Our aim was to evaluate the association of HCV treatment with survival and assess barriers to treatment. Methods: Patients in the U.S. Safety Net Collaborative with HCV and HCC were included. Primary outcome was overall survival (OS). Secondary outcomes were recurrence-free survival (RFS) and barriers to receiving HCV treatment. Results: Of 941 patients, 57% received care at tertiary referral centers (n=533), 74% did not receive HCV treatment (n=696), 6% underwent resection (n=54), 17% liver transplant (n=163), 50% liver-directed therapy (n=473), and 7% chemotherapy (n=60). HCV treatment was associated with improved OS compared to no HCV treatment (70 vs 21 months, p<0.01), persisting across clinical stages, HCC treatment modalities, and treatment facilities (all p<0.01). Surgical patients who received HCV treatment had improved RFS compared to those who did not (91 vs 80 months, p=0.03). On MVA, HCV treated patients had improved OS and RFS. On MVA, factors associated with failure to receive HCV treatment included Black race, higher MELD, and advanced clinical stage (all p<0.05). Conclusion: HCV treatment for HCC patients portends improved survival, regardless of clinical stage, HCC treatment, or facility type. Efforts must address barriers to HCV treatment.

Original languageEnglish (US)
JournalHPB
DOIs
StateAccepted/In press - 2020

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Impact of hepatitis C treatment on long-term outcomes for patients with hepatocellular carcinoma: a United States Safety Net Collaborative Study'. Together they form a unique fingerprint.

  • Cite this

    Turgeon, M. K., Lee, R. M., Gamboa, A. C., Yopp, A., Ryon, E. L., Goel, N., Wang, A., Lee, A. Y., Luu, S., Hsu, C., Silberfein, E., Maithel, S. K., & Russell, M. C. (Accepted/In press). Impact of hepatitis C treatment on long-term outcomes for patients with hepatocellular carcinoma: a United States Safety Net Collaborative Study. HPB. https://doi.org/10.1016/j.hpb.2020.07.012